M onitoring human immunodeficiency virus (HIV) incidence rates over time facilitates informed public health decisions on HIV prevention and treatment. Longitudinal studies are commonly used to estimate incidence rates where test dates are scheduled at fixed time intervals of, say, every month or year. 1 The timing of a new infection can be assumed to be within the seroconversion interval of the last-negative and first-positive test dates, as either the midpoint or a random-point value. Recently, these 2 popular approaches for identifying the timing of seroconversion in estimating incidence rates have been discussed but little is still known about how these approaches influence interpretation of HIV incidence trends under different circumstances in cohorts for women at high-risk of HIV. 2 Globally, HIV risk is 13 times higher among female sex workers (FSWs) than among other adult women. 3 The HIV incidence in FSW studies in eastern and southern Africa is as high as 9.8/100 personyears. 4 In Uganda, where adult female HIV prevalence is 7.5%, estimated prevalence among FSWs varies between 32% and 52%. 5, 6 Using data on HIV-1-specific immunoglobulin G (IgG) levels that indicates if a patient was infected recently, assuming the midpoint value while estimating incidence was appropriate for cohort studies with regular testing intervals. 7 However, a recent simulation study estimating incidence trends demonstrated that, in the presence of missed scheduled testing, the midpoint approach leads to an artefactual clustering of seroconversion times in the middle of the observation period. 2 As a result, incidence rates are underestimated at the beginning and at the end of the observation period, and overestimated in the middle. For example, incidence rates at the end of the observation period were in error of 27% for a simulated cohort with a 40% to 59.9% testing rate. An alternative approach that randomly assigns the timing of seroconversion within the seroconversion interval produced less biased incidence trend estimates. 2 Several factors can lead to varying visit attendance rates during observation. In follow-up studies of long durations, later observation periods usually have poorer attendance rates than earlier ones, partly due to participation fatigue. 8 Changes in certain cohort activities, such as removing transport refund, can also influence levels of attendance during those periods. In particular, cohorts for high-risk populations are vulnerable to missing visits and prematurely discontinuing participation (attrition) because of the high mobility of participants and transport costs among other reasons. 9, 10 The longer seroconversion intervals due to missed visits create larger uncertainty over when the event occurs, and attrition leads to uncertainty of whether the event occurs for participants defined with attrition. These uncertainties can compromise the interpretations of HIV incidence trends. 8 Participants with attrition are usually censored at their last observation, whereas assuming their risk of infection at censoring is the same as that in those under observation at that time-point. If this assumption is violated, for instance, if women who discontinue are at a higher risk of HIV than those who remain in the study, then there is potential for bias in incidence estimates. Given the cohort experience of participants without attrition who have similar characteristics as those with attrition, using multiple imputation (MI) to predict unobserved HIV serostatus and timing of seroconversion for women with attrition could improve the accuracy of incidence estimates.
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In this article, we aim to compare HIV incidence trends based on 3 approaches: (1) estimating the date of seroconversion within the seroconversion interval using the midpoint, (2) estimating the date of seroconversion within the seroconversion interval using the random-point method, and (3) predicting the time-to-event data using MI for women with attrition. These comparisons are performed in the epidemiological context of a dedicated clinic which has been providing services to women at high-risk of HIV in Kampala, Uganda since 2008.
METHODS

Cohort Description
The Good Health for Women Project (GHWP) is a stand-alone clinic offering free services to women at high-risk of HIV-infection in Kampala, Uganda. 12 Briefly, peer educators recruited other women involved in commercial sex or employed in an entertainment facility within mapped sex work hotspots (eg, clusters of bars, night clubs, lodges, and guest houses providing rooms for sex work, street spots frequented by sex workers). Outreach workers visited these women at their workplace to assess eligibility. Women were eligible if 18 years or older and reported engaging in commercial sex (self-identified FSWs or received money, goods, or other favors in exchange for sex) or employed in an entertainment facility. Women younger than 18 years were eligible if pregnant, had a child, or provided for their own livelihood. Those eligible were invited to attend the clinic for screening and enrolment.
Women were initially enrolled into cohort 1 between April 2008 and May 2009 and continually scheduled for follow-up once every 3 months. Previous publications on this cohort have examined prevalence of HIVand other STIs at baseline, 12 HIV incidence and risk factors using data up to March 2011, 13 and the epidemiology of alcohol use until September 2013.
14 Cohort 2 was started in January 2013 with continuous enrolment of participants and identical follow-up procedures as cohort 1. This article considered follow-up visits up to August 29, 2017, for both cohorts.
Study Intervention
The program integrates sex worker-friendly HIVand sexual and reproductive health services, including offering free general health care for participants and their children younger than 5 years. Figure 1 shows a summarized conceptual framework guiding the GHWP intervention derived from the standard framework for preventing HIV acquisition in FSWs developed by World Health Organization. The intervention can be categorized into 3 broad components (behavioral, biomedical, structural) aiming at 3 broad categories of immediate outcomes: reducing unprotected sex, decreasing HIV transmission efficiency, and empowering FSWs. 15, 16 The horizontal arrows depict the link from the intervention to the intermediate effects, which in turn determine the impact on HIV acquisition and transmission. The vertical arrows show the factors that can influence the immediate intervention effects, and the transition to HIV prevention indicators. To ensure high cohort retention, group meetings were held every 14 days with women who had scheduled visits within the following month. 
Data
At every visit, HIV testing was performed using determine HIV-1/2 (Abbott Diagnostics, UK) for screening and a reactive result was confirmed by Stat-Pak dipstick HIV-1/2 (Chembio Diagnostics, US). The Uni-Gold HIV-1/2 (Trinity Biotech, Ireland) was used as a tie breaker if Determine and Stat-Pak were discordant. At every visit, trained nurse counselors administered structured questionnaires to collect data on sociodemographic characteristics, sexual behavior, reproductive health, alcohol use, and illicit drug use.
Statistical Analysis
Analyses were restricted to HIV-negative women enrolled before May 2017 to allow for follow-up visits for all participants. In estimating incidence, the endpoint for calculating person-years at risk was the earliest of (i) estimated HIV seroconversion date for seroconverters or (ii) last HIV-negative test date for nonseroconverters.
The HIV seroconversion date was estimated using (a) midpoint between last-negative and first-positive HIV test dates, (b) random-point method. The random-point method assumed seroconversion to be a random date from a uniform distribution bounded by the last-negative and first-positive test dates. To account for the variability of using a random date, multiple imputations were made, and incidence rates over time were estimated each time and averaged at each time-point for all iterations.
To assess the potential consequence of attrition on incidence trends, we imputed the unobserved HIV serostatus then obtained timing for seroconversion for participants with attrition. Several methods for imputing unobserved time-to-event endpoints have been published. 17, 18 Because our interest is incidence trends evaluated at time intervals of follow-up, we applied an MI approach that models the probability of seroconversion within each time interval given that the participant was HIV-negative up to the start of that interval. In this approach, the follow-up period is divided into discrete intervals of time and logistic regression used to impute serostatus sequentially in each interval. Then, the imputed serostatuses are mapped back to the time scale by allocating a random time within the seroconversion interval, and censoring at each participant's expected complete follow-up time for imputed nonseroconverters. Estimates were based on 200 imputations. The log of incidence rates at each time interval were estimated separately in each imputed data set, then averaged using Rubin's rules. 19 Statistical tests assessing whether *Most missing data were due to programming errors in the electronic data capture system as the system was rolled-out starting in January 2015.
the age-adjusted incidence trends changed over time in each imputed data set were combined after normalization using Wilson-Hilferty transformation. 20 The imputation model included factors associated with both attrition and HIV incidence in this analysis. To improve imputation accuracy of serostatus, we included as a priori the age and time-varying characteristics of the following: frequency of alcohol consumption, reporting paid sex, condom use frequency with paid sex, and number of partners in the last month in the imputation models. To identify factors associated with attrition, the outcome was time to attrition, and follow-up was right-censored at last observation. A participant had attrition if their last study attendance was 12 months or more before the administrative censoring date, consistent with what has been used in other studies. To investigate factors associated with attrition and then incidence, hazard ratio, and associated 95% confidence intervals (CI) and P values were estimated using Cox regression models. Age-adjusted models were fitted separately for each factor and independently associated sociodemographic factors (P ≤ 0.15) were determined. These were then adjusted for behavioral and reproductive health factors that remained statistically significant at 15% level. Time-changing variables were fitted using the most recent reports at each visit.
Analyses were performed separately for each cohort because of the potential variation in exposures due to the 5-year gap between the starts of the 2 cohorts. For each cohort, estimates of incidence trends from 3 models were compared: (1) without MI using midpoint, (2) without MI using random-point, (3) MI using random-point. Changes in incidence trends were assessed using Poisson regressions models by testing the inclusion of a linear and a quadratic trend with time in models adjusted for current age. Stata 14 (StataCorp, Tx) was used for all analyses.
RESULTS
Human immunodeficiency virus prevalence at enrolment was 37.0% (380 of 1027) in cohort 1 and 35.4% (1335 of 3772) in cohort 2. Table 1 shows enrolment characteristics for the 3084 HIV-negative women. Overall, the mean age was 26.2 years (SD, 6.3 years) with over 80% having 1 child or more. Most (58.0%) reported their only source of income as sex work, and 37.2% reported having another job in addition to sex work.
Attrition and Missed Visits
The percentage of women with 1 or more follow-up visit was 93.5% (605 of 647) in cohort 1 and 65.7% (1601 of 2437) in cohort 2. A total of 32,762 visits (cohort 1, 17,970; cohort 2, 14,792) were expected, whereas 18,364 (cohort 1, 9,504; cohort 2, 8,860) were made. Before attrition, 6990 visits (cohort 1, 3324; cohort 2, 3666) were missed and 7408 (cohort 1, 5142; cohort 2, 2266) after attrition. Table 2 shows study participation, and the supplementary Table 1 (SDC link http://links.lww.com/OLQ/ A343) shows the factors associated with attrition. Attrition was independently associated with follow-up characteristics of having no child, being pregnant, recruiting clients on phone, and reporting no illicit drug use in the last 3 months in cohort 1 and younger age, not using oral contraceptives, and less frequent paid sex in the last year in cohort 2. The percentage of participants attending each visit with 1 or more missed visits since the previous attendance in cohort 1 was stable at 10% until year 4, when this proportion increased to an average of 30% for all the visits after year 4 (Fig. 2) . In cohort 2, this proportion was stable at 30% for all the visits after enrolment.
HIV Incidence
Among 2206 HIV-negative participants with 1 or more follow-up visits, 170 were observed to seroconvert within 5543 person-years Supplementary Table 2 (SDC link http://links.lww. com/OLQ/A344). Without MI, the midpoint and random-point incidence trends were similar in the first 4 years of enrolment and at years 7 and 8 of cohort 1 (Fig. 3) . At the introduction of cohort 2 in January 2013, corresponding to years 5 and 6, the random-point method attenuated the variation observed using midpoint estimation (Fig. 3A) . The median length of the seroconversion interval was 3.4 months (interquartile range [IQR], 3.0-7.1) for cohort 1 participants whose last-negative test date occurred before January 2013, and 10.1 months (IQR, 5.8-18.3) between January 2013 and December 2014, and 3.9 months (IQR, 2.5-5.5) after January 2015. In cohort 2, the median was 14.9 months (IQR, 4.7-26.9) between January 2013 and December 2014, and 5.6 months (IQR, 3.2-7.7) after January 2015. In cohort 2 without MI, incidence based on midpoint increased between the first and second intervals peaked at year 2 then decreased steeply at the end of the observation period, whereas that based on random-point dropped from its peak at the first interval and decreased further in the last interval (Fig. 3B) .
In cohort 1, incidences based on MI using random-point estimation for attrition were higher than without MI (using either method), particularly starting from year 5. In cohort 2, the overlapping 95% CIs for incidences are consistent with no differences between MI and without MI approaches (Table 3) .
Based on random-point without MI for attrition, there was a sharp fall in incidence from 6.1/100 person-years within the first 6 months to 2.5 of 100 in the following 6 months, and then 2.0/ 100 at year 3 in cohort 1 (age-adjusted trend P < 0.001). After the fourth year, incidence increased to 3.8/100 person-years at the end of the observation period but there was weak evidence to suggest a changing trend (age-adjusted P = 0.15). In cohort 2, *Cohort retention defined as the number of women followed up to each time interval including those who had seroconverted among those who should have been followed by that time point. † A participant is classified with attrition (drop-out) if their last attended visit was 12 months or more before August 29, 2017. Participants were administratively censored if their last attended visit was within the last 12 months from the administrative date of August 29, 2017. ‡ Participants expected at the start of each interval for cohort 2 vary because of continuous enrolment, meaning that to be included in an interval the participant should have been enrolled for that duration. § For cohort 2, the last interval of follow-up ends at time interval of 3-4 years. incidence declined from 3.8/100 person-years in the first 6 months to 1.8/100 in year 3 (age-adjusted P = 0.04).
DISCUSSION
Our findings suggest that the variations in incidence patterns observed with assigning midpoints within seroconversion intervals were attenuated if random-points were assigned instead. With long seroconversion intervals spanning the observation period, incidences based on midpoint were lower at the beginning and at the end of the observation than in the middle where incidence peaked (cohort 2). Where long seroconversion intervals were concentrated in the middle of observation periods with short seroconversion intervals, there were larger fluctuations in incidences over time during that middle period using the midpoint than the random-point approach (cohort 1). Multiple imputation for unobserved HIV serostatus and time-to-seroconversion for women defined with attrition showed noticeably higher incidences than without MI after an escalated attrition of participants (year 5 in cohort 1 and year 1 in cohort 2).
An incidence peak in the middle of the observation period and lower incidence at the beginning and at the end using the midpoint approach is consistent with results from a recent simulation study where incidence was underestimated at the beginning and at the end of the observation and overestimated in the middle. 2 This midpoint behavior is a result of clustering of the seroconversion timing in the middle of the observation period. The authors observed this pattern with a large extent of missed scheduled test dates irrespective of the true incidence trend, cohort type and number of scheduled test dates. However, they described incidence patterns where irregular HIV testing spans the entire observation period, similar to what we observe in cohort 2. Conversely, in their study the random-point assignment of seroconversion date which was less restrictive than the midpoint showed less biased incidence trends.
Cohort 1 had much longer seroconversion intervals in the period spanning years 5 and 6 than during the first 4 years and years 7 and 8. This resulted in similar incidences for the random-point and midpoint approaches in the period with shorter seroconversion intervals and noticeable differences in the period with longer seroconversion intervals. In 2013 and 2014, peer educators who were instrumental in study recruitment involving highrisk populations were not paid allowances. This, together with not providing transport compensation for participants, had a negative effect on visit attendance leading to longer seroconversion intervals and a subsequent clustering of seroconversion timing at year 5 but offset at the following year.
Although participants in years 7 and 8 had irregular visit attendance similar to that in years 5 and 6, they had shorter seroconversion intervals suggesting that the length of the seroconversion intervals rather than irregular visit attendance determine the extent of differences between the 2 approaches. If for some reason there is irregular visit attendance in general but the seroconversion intervals are shorter, then there would be little differences between the approaches.
In both cohorts, the higher MI-based than non-MI incidences after escalated attrition of participants suggests attrition of more-risky participants, given previously reported characteristics. However, it is likely that the estimated MI-based incidences after marked attrition may be overestimated if some participants dropped-out because they perceived themselves to be low-risk, for example, exited sex work but reported high-risk behaviors at the prior visit. For cohort 1, escalated attrition occurred at a time-point corresponding to the estimated mean duration of risk behaviors for FSWs in Africa of 5.5 years, as reported in a review of duration of risk behaviors in key populations. 21 Overall, these MI-based estimates suggest that incidences obtained without MI may have been underestimated after escalated attrition.
A key limitation in this study is the use of self-reported data in predicting serostatus for women with attrition, which data is subject to social desirability and can ultimately affect MI-based incidence estimates. Also, some women defined with attrition in our study may be accessing services elsewhere including private services, may have exited sex work, or are living less-risky lifestyles yet their un-observed predicted serostatus is based on previously reported high-risk behaviors. Therefore, combined with the lack of proper data on the reasons for exit and data on mortality, the MI-based incidences may have been overestimated. In addition, missing data in some women, which was used to perform MI, could potentially skew conclusions. However, we assumed these data were missing completely at random because most of the missingness was due to the electronic data capture system failing to capture data at roll-out during cohort 2. Nonetheless, it is unlikely that these observations could have substantially changed our conclusions.
In conclusion, the random-point approach reduced the improbable fluctuations in incidence and incidence patterns observed with midpoint in the presence of long seroconversion intervals. Based on random-point without MI, the HIV incidence declines in the 3 years after enrolment of 67% in cohort 1 and 53% in cohort 2 were substantial but incidence remains high. The declines in HIV incidence over time are likely due to the ongoing interventions but the high incidence rates after years of potential exposure to the intervention suggests a need for further strengthening the intervention efforts in this cohort. In particular, the factors influencing the slight rise in incidence after 4 years among cohort 1 participants are not well understood, but these changes coincide with the period with substantial proportions of missed visits. We are currently examining some of these factors in more detail. Despite the importance of tracking HIV incidence trends in this vulnerable population, there was paucity of recent incidence data with which to compare our findings. 10, 21, 22 In choosing how to assign the seroconversion timing and interpreting the resulting incidence patterns, it is important to consider the changes in the extent of missed visits and length of seroconversion intervals over time.
